Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody

被引:11
|
作者
Yanagida, Mitsuaki [1 ]
Kawasaki, Mikiko [1 ]
Fujishiro, Maki [1 ]
Miura, Masako [1 ]
Ikeda, Keigo [2 ]
Nozawa, Kazuhisa [3 ]
Kaneko, Hiroshi [4 ]
Morimoto, Shinji [2 ]
Takasaki, Yoshinari [3 ]
Ogawa, Hideoki [1 ]
Takamori, Kenji [1 ]
Sekigawa, Iwao [1 ,2 ]
机构
[1] Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, Urayasu, Chiba 2790021, Japan
[2] Juntendo Univ, Urayasu Hosp, Dept Internal Med, Urayasu, Chiba 2790021, Japan
[3] Juntendo Univ, Sch Med, Dept Internal Med & Rheumatol, Bunkyo Ku, Tokyo 1138421, Japan
[4] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Rheumatol, Ichikawa, Chiba 2728516, Japan
关键词
MOLECULAR-WEIGHT; DISEASE-ACTIVITY; ALPHA ANTIBODY; GLYCOPROTEIN; ASSOCIATION; PROGRESSION; BIOMARKER; ANDROGEN; MARKER; MUC18;
D O I
10.1155/2013/607137
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. Tocilizumab is a biological agent and an anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6-mediated inflammatory processes in RA patients. In order to identify novel disease-related proteins and candidate biomarkers, we analyzed the changes in the serum proteome profiles of patients with RA who were treated with tocilizumab. Serum samples were collected from the RA patients before and after tocilizumab treatment. Following immunodepletion of major proteins, the proteins were digested and labeled with isobaric tag, iTRAQ reagent. The proteins were identified and quantified using liquid chromatography-tandem mass spectrometry. Among a total of 311 proteins identified, seven were decreased and 16 were increased by tocilizumab treatment. Although some of the proteins are known to be related to RA, several are currently unknown with respect to their relationship to RA and may be involved in the development of this disease. This study is the first to perform a comparative serum proteomic analysis of RA patients treated with tocilizumab. Our results may contribute to the identification of novel disease-related proteins and enhance the understanding of the pathogenesis of RA.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
    Kawashiri, Shin-ya
    Kawakami, Atsushi
    Yamasaki, Satoshi
    Imazato, Takahiro
    Iwamoto, Naoki
    Fujikawa, Keita
    Aramaki, Toshiyuki
    Tamai, Mami
    Nakamura, Hideki
    Ida, Hiroaki
    Origuchi, Tomoki
    Ueki, Yukitaka
    Eguchi, Katsumi
    [J]. RHEUMATOLOGY INTERNATIONAL, 2011, 31 (04) : 451 - 456
  • [2] Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
    Shin-ya Kawashiri
    Atsushi Kawakami
    Satoshi Yamasaki
    Takahiro Imazato
    Naoki Iwamoto
    Keita Fujikawa
    Toshiyuki Aramaki
    Mami Tamai
    Hideki Nakamura
    Hiroaki Ida
    Tomoki Origuchi
    Yukitaka Ueki
    Katsumi Eguchi
    [J]. Rheumatology International, 2011, 31 : 451 - 456
  • [3] Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
    Mihara, Masahiko
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    [J]. OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2011, 3 : 19 - 29
  • [4] Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis
    Hoffman, Elinoar
    Rahat, Michal A.
    Feld, Joy
    Elias, Muna
    Rosner, Itzhak
    Kaly, Lisa
    Lavie, Idit
    Gazitt, Tal
    Zisman, Devy
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (18)
  • [5] EFFECTS OF TOCILIZUMAB, AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, ON SERUM LIPID AND ADIPOKINE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hoffman, E.
    Rahat, M. A.
    Feld, J.
    Elias, M.
    Rosner, I.
    Kaly, L.
    Lavi, I.
    Zisman, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 318 - 318
  • [6] Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis
    Hirabayashi, Yasuhiko
    [J]. MODERN RHEUMATOLOGY, 2021, 31 (01) : 70 - 79
  • [7] Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1677 - 1691
  • [8] Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics
    Kawashiri, Shin-ya
    Kawakami, Atsushi
    Iwamoto, Naoki
    Fujikawa, Keita
    Aramaki, Toshiyuki
    Tamai, Mami
    Arima, Kazuhiko
    Ichinose, Kunihiro
    Kamachi, Makoto
    Yamasaki, Satoshi
    Nakamura, Hideki
    Origuchi, Tomoki
    Ida, Hiroaki
    Eguchi, Katsumi
    [J]. MODERN RHEUMATOLOGY, 2010, 20 (01) : 40 - 45
  • [9] Anti-Interleukin-6 Therapy in Rheumatoid Arthritis
    Woodrick, Robert
    Ruderman, Eric M.
    [J]. BULLETIN OF THE HOSPITAL FOR JOINT DISEASES, 2010, 68 (03): : 211 - 217
  • [10] Successful Treatment of Reactive Arthritis With a Humanized Anti-Interleukin-6 Receptor Antibody, Tocilizumab
    Tanaka, Toshio
    Kuwahara, Yusuke
    Shima, Yoshihito
    Hirano, Toru
    Kawai, Mari
    Ogawa, Masako
    Arimitsu, Junsuke
    Hagihara, Keisuke
    Narazaki, Masashi
    Ogata, Atsushi
    Kawase, Ichiro
    Kishimoto, Tadamitsu
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (12): : 1762 - 1764